RxDoctor Payments Data

Eileen Smith, MD

Dermatology · Walla Walla, WANPI 1558340554

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $40,250 of the $49,264 with a category attached, or 81.7%. AbbVie accounts for 62.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $41,885 and has fallen 99.7% since, to $146 in 2024. Among dermatology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$49,264in general payments, 2019–2025

Across 126 payments — averaging $390.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$31K
  • Novartis$12K
  • Pfizer$3K
  • UCB, Inc.$2K
  • Lilly USA, LLC$475
  • Bristol Myers Squibb$176
  • plus $750 from 13 others
$41,403in research payments, 2019–2025

Across 18 payments — averaging $2300.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$27K
  • Bausch Health US, LLC$14K
  • Janssen Research & Development, LLC$1K
  • LEO Pharma AS$200

What the payments were for

  • Consulting fees$1,6803%
  • Speaking & faculty fees$40,25082%
  • Travel & lodging$3,8208%
  • Food & beverage$3,4007%
  • Education$1140%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,264 in reported general payments places this provider in the 95th percentile of 323 dermatology providers in Washington.

See all dermatology providers in Washington

Medicare billing

Part B allowed, 2024
$52,113
Medicare patients
320
Services billed
1,775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast17$78,315
Metronidazole12$546
Hydroxychloroquine Sulfate13$504
Triamcinolone Acetonide32$253
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc21$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$16$78,31517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 dermatology providers in Washington.

Other dermatology in Walla Walla

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →